Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - SOLESENCE, INC. (0000883107) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
3 - SOLESENCE, INC. (0000883107) (Issuer)
4 - SOLESENCE, INC. (0000883107) (Issuer)
4 - SOLESENCE, INC. (0000883107) (Issuer)
Fastest customizable press release news feed in the world
ROMEOVILLE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company's expansion and innovation, will assume the role of President and Chief Executive Officer. Laura Riffner has been appointed Chief Financial Officer, bringing decades of financial expertise in enhancing operational excellence and efficiency. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company
ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025. Recent Highlights and Accomplishments Joined broad-market Russell 3000® and small-cap Russell 2000® IndexesAmended loan agreements to fuel growth initiatives "During our seasonally highest-performing quarter, we're pleased with the effectiveness of our commercial execution and the consistent, on-time delivery of products to our partners," said Jess Jankowski, President and Chief Executive Officer of Solésence. "Innovation
ROMEOVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the second quarter of 2025 after the market close on Thursday, July 31, 2025, and host a conference call and webcast on the same date. Second Quarter 2025 Conference Call Details Date / Time: Thursday, July 31, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/7n5uumgk Dial-In Link: https://register-conf.media-server.com/register/
ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be added as a member of the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or
ROMEOVILLE, Ill., June 02, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it entered into amendments on May 27, 2025 to its existing loan agreements, providing increased borrowing capacity to support the execution of strategic objectives. The new facility expands the Company's three loan agreements to a maximum borrowing capacity from $14.2 million to $23.0 million and extends the maturity date under each respective loan agreement from October 1, 2025 to April 30, 2027. The additional borrowing capacity provides Solésence with significant financial flexibil
First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker "SLSN" supporting the Company's increased visibility with the investment communityAchieved record revenue and unit volume shipments in the first quarter 2025 "We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products," said Jess Jankowski, President and
ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2025 after the market close on Monday, May 5, 2025, and host a conference call and webcast on the same date. First Quarter 2025 Conference Call Details Date / Time: Monday, May 5, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/q53hzimg Dial-In Link: https://register-conf.
8-K - SOLESENCE, INC. (0000883107) (Filer)
8-K - SOLESENCE, INC. (0000883107) (Filer)
10-Q - SOLESENCE, INC. (0000883107) (Filer)
8-K - SOLESENCE, INC. (0000883107) (Filer)
DEF 14A - SOLESENCE, INC. (0000883107) (Filer)
8-K - SOLESENCE, INC. (0000883107) (Filer)
10-Q - SOLESENCE, INC. (0000883107) (Filer)
8-K - SOLESENCE, INC. (0000883107) (Filer)
Live Leadership Updates
ROMEOVILLE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced strategic changes to its executive leadership. Kevin Cureton, a driving force behind the company's expansion and innovation, will assume the role of President and Chief Executive Officer. Laura Riffner has been appointed Chief Financial Officer, bringing decades of financial expertise in enhancing operational excellence and efficiency. Jess Jankowski, who has been at the helm of the company as Chief Executive Officer since 2009, will serve as Board Advisor until his retirement from the company
ROMEOVILLE, Ill., June 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that it will be added as a member of the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market opens on June 30, as part of the 2025 Russell indexes reconstitution. The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000® Index, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or
Live finance-specific insights
ROMEOVILLE, Ill., July 31, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the second quarter ended June 30, 2025. Recent Highlights and Accomplishments Joined broad-market Russell 3000® and small-cap Russell 2000® IndexesAmended loan agreements to fuel growth initiatives "During our seasonally highest-performing quarter, we're pleased with the effectiveness of our commercial execution and the consistent, on-time delivery of products to our partners," said Jess Jankowski, President and Chief Executive Officer of Solésence. "Innovation
ROMEOVILLE, Ill., July 24, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the second quarter of 2025 after the market close on Thursday, July 31, 2025, and host a conference call and webcast on the same date. Second Quarter 2025 Conference Call Details Date / Time: Thursday, July 31, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/7n5uumgk Dial-In Link: https://register-conf.media-server.com/register/
First quarter revenue increased 48% to a record $14.6 million ROMEOVILLE, Ill., May 05, 2025 (GLOBE NEWSWIRE) -- Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced financial results for the first quarter ended March 31, 2025. Recent Highlights and Accomplishments Uplisted to Nasdaq under the ticker "SLSN" supporting the Company's increased visibility with the investment communityAchieved record revenue and unit volume shipments in the first quarter 2025 "We kicked off 2025 with record revenue, fueled by strong sales across our suite of consumer products," said Jess Jankowski, President and
ROMEOVILLE, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Romeoville, Ill., April 28, 2025 – Solésence, Inc. (NASDAQ:SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced that the Company will report results for the first quarter of 2025 after the market close on Monday, May 5, 2025, and host a conference call and webcast on the same date. First Quarter 2025 Conference Call Details Date / Time: Monday, May 5, 2025 - 4:00 p.m. CDT, 5:00 p.m. EDT Speakers: Jess Jankowski, President & CEO, and Kevin Cureton, Chief Operating Officer Webcast Link: https://edge.media-server.com/mmc/p/q53hzimg Dial-In Link: https://register-conf.